Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Mult Scler. 2018 May 18;24(8):1014–1022. doi: 10.1177/1352458518775550

Table 2.

Changes to lymphocyte populations in response to immunotherapy in MS patients.

Aging Natalizumab Fingolimod DMF Anti-CD20 Teriflunomide Alemtuzumab
PERIPHERY CD19+ B cells ▼▼ ▼▼ ▼▼▼ ▼▼ ▼▼
B memory
B naïve
B regulatory
CD3+ T cells ▼▼ ▼▼ ▼▼▼
T naïve
T memory
T regulatory
CD4+ T cells ▼▼ ▬/▼ ▼▼▼
TCentral Memory ▭/△ ▭/△
TEffector Memory
THelper 1
THelper 17
THelper 2
CD8+ T cells ▬/▲ ▼▼ ▼▼▼
TCentral Memory
TEffector Memory
TEMRA
CD4+/CD8+ ▬/▼ ▬/▼
CNS CD19+ B cells ▼▼ ▼▼▼
B memory
B naïve
B regulatory
CD3+ T cells ▼▼ ▼▼ ▼▼
CD4+ T cells ▼▼ ▼▼
CD8+ T cells
T regulatory
CD4+/CD8+

Bold font and closed symbols indicates changes in absolute cell numbers.

Regular font and open symbols indicates relative changes.

▲ Increase, ▼ Decrease, ▬ No change, use of / indicates different effects in different subsets of patients. Magnitude of absolute cell count changes noted by number of symbols. Empty boxes indicate no reported data.